therapy do not maintain miR-155 downregulation. The relevance of our findings are significant as they use cellular miR-155 levels to risk stratify CLL patients receiving chemoimmunotherapy and also identify an effective therapeutic, ibrutinib, which targets the critical BCR signaling pathway, which can downmodulate a leukemogenic miR.
The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells Leukemia (2015) 29, 1213-1218; doi:10.1038/leu.2014.345
Classical Hodgkin lymphoma (HL) is a common lymphoid malignancy that displays unique features with respect to morphology, tumor biology and clinical presentation. Histologically, classical HL is characterized by large mononuclear Hodgkin and multinucleated Reed-Sternberg (HRS) cells. A hallmark of HL cells is the highly inflammatory phenotype. Typically, the malignant HRS cells represent only a minor fraction of the affected lymph nodes and are surrounded by numerous benign reactive cells, including lymphocytes, macrophages and granulocytes. These inflammatory cells are attracted by cytokines and chemokines secreted by the malignant cell population. 1, 2 Accepted article preview online 9 December 2014; advance online publication, 27 January 2015
The complex interactions between HRS cells and bystander cells create a specific microenvironment that is thought to be critical for growth and survival of HRS cells. A detailed analysis of signals evoked by these interactions does not only contribute to a better understanding of HL pathogenesis, but might also provide a basis for the development of new treatment strategies. Here, we describe an aberrant expression and activity of the interleukin 15 (IL-15) cytokine/cytokine receptor system in HL resulting in mitogenic and anti-apoptotic signals, as well as the enhanced expression of inflammatory factors by HRS cells. IL-15 is a proinflammatory cytokine that was originally identified through its ability to induce T-cell proliferation, displaying IL-2-like properties. 3 Indeed, both cytokines act through a heterotrimeric receptor that shares the IL-2 receptor β (IL-2Rβ, also referred to as IL-15Rβ, CD122) and the common γ chain (IL-2Rγ, CD132). However, high-affinity binding specificity for each ligand is conferred by a unique subunit, namely IL-2Rα and IL-15Rα, respectively. 3 Functionally, IL-15 has a pivotal role in the differentiation and/or survival of natural killer (NK) cells, NK T cells as well as intraepithelial lymphocytes and is critical for the maintenance of CD8 + memory T cells. 4 To identify factors that are involved in the formation of the HLspecific tumor microenvironment, we screened microarray gene expression profiles of HRS and B non-Hodgkin cell lines with a special focus on cytokines and cytokine receptors . In addition to  several factors known to be highly expressed by HRS cells, such as  IL-6, IL-13 and IL-13Rα, we identified an upregulation of IL-15 and  the corresponding receptor components IL-15Rα, IL-2Rβ/IL-15Rβ and IL-2Rγ in Hodgkin-derived cell lines ( Supplementary Figure 1) . Given the role of IL-15 as a prominent pro-inflammatory cytokine and its growth-supporting effects on several lymphoid cell populations, we decided to investigate the role of IL-15 in HL in more detail. First, we examined the expression status of IL-15 and its receptor components in a broad panel of lymphoma-derived cell lines. As determined by quantitative PCR, most HL cell lines showed a strong upregulation of IL-15 mRNA compared with non-Hodgkin B-cell lines (Figure 1a ). For IL-15Rα and IL-2Rβ/IL-15Rβ mRNA, we observed a similar overexpression in HL cell lines, whereas the mRNA for the common γ chain (IL-2Rγ) was ubiquitously expressed in all the cell lines tested (Figure 1a ). Subsequently, the expression of the IL-15 receptor components was analyzed on protein level by flow cytometry, corroborating enhanced expression of IL-15Rα and IL-2/IL-15Rβ on HRS cell lines ( Figure 1b ). (c) Immunohistochemistry for IL-15 in fresh frozen samples of reactive tonsils and primary HL tissue. Antigen detection was carried out with an anti-IL-15 mouse monoclonal antibody or a corresponding isotype control. Bound antibody was detected with polyclonal rabbit anti-mouse immunoglobulin and visualized using the alkaline phosphatase anti-alkaline phosphatase (APAAP) method.
To investigate the expression of IL-15 in primary HL cases, we performed immunohistochemical staining on frozen sections of control and HL tissue samples. Immunohistochemistry of nonmalignant reactive tonsils demonstrated specific staining for IL-15 predominantly in cells displaying macrophage or dendritic cell morphology, a feature that was particularly apparent in germinal centers, most likely corresponding to follicular dendritic cells, 5 whereas germinal center B cells themselves were negative ( Figure 1c ). Moreover, immunohistochemistry revealed IL-15 expression in HRS cells in a series of eight primary HL cases with variable percentages of positive cells (Figure 1c ; Supplementary  Table 1 ). In addition, cells of the tumor microenvironment stained positive for IL-15, including cells with monocytic/dendritic morphology and endothelial cells, which is in accordance with previous studies describing IL-15 expression in these cell types. [6] [7] [8] These observations suggest that two sources of IL-15 exist in HLaffected lymph nodes, which might act either in an autocrine or paracrine manner on HRS cells.
Next, we investigated the functional role of IL-15 signaling in HRS cells. To this end, HRS cell lines were stimulated with recombinant human (rh) IL-15 and the activation status of intracellular signaling pathways, which have been described to respond to IL-15 in other cellular systems, 9 was monitored in a time-and dose-dependent manner. Stimulation with rhIL-15 induced the phosphorylation of the mitogen-activated protein (MAP) kinases ERK1/2 as well as STAT5 in HRS cell lines, showing the most pronounced effects on STAT5 activation (Figure 2a ). Furthermore, we observed an increased proliferation of KM-H2 and L591 HRS cells after IL-15 stimulation as determined by [ 3 H]thymidine incorporation (Figure 2b ). Next, we analyzed whether IL-15 mediates survival signals for HRS cells, especially in the context of cellular stress evoked by treatment with chemotherapeutic agents. For this purpose, KM-H2 cells were pre-stimulated with rhIL-15 and subsequently treated with etoposide or doxorubicin, which are part of HL treatment regimens, or geldanamycin, a pharmacologic inhibitor of heat shock protein 90 (HSP90) and NF-κB signaling. 10 Measuring the percentage of viable and apoptotic cells by annexin V-FITC/propidium iodide staining and flow cytometry, we observed that pre-treatment with rhIL-15 is able to mitigate drug-induced cell death in the KM-H2 (Figure 2c ). Furthermore, cells were stained in parallel with an antibody that recognizes active caspase 3, which is an indicator of ongoing programmed cell death, revealing a lower percentage of apoptotic cells in rhIL-15 pre-treated KM-H2 cells (Figure 2c ).
To gain insight into the molecular mechanisms of IL-15 signaling in HRS cells, we performed oligonucleotide microarray analysis of KM-H2 cells following rhIL-15 stimulation. Gene expression profiles of KM-H2 cells were determined at 0, 4, 10 and 24 h of rhIL-15 treatment and normalized to profiles of PBStreated KM-H2 cells that were analyzed in parallel to control for expression changes induced by growth in cell culture per se. This approach identified a specific set of genes that showed a significant regulation by rhIL-15 at the respective time points, with 43 genes being differentially expressed at 24 h (with a fold change of at least log2 0.75 ; Supplementary Table 2 ). To identify biological processes regulated by IL-15, we used the DAVID classification tool that classifies gene lists into functionally related gene groups. In accordance with our functional data, we observed a significant enrichment of gene ontology terms associated with cellular proliferation and survival within our set of rhIL-15regulated genes ( Supplementary Table 3 ). Remarkably, we also found a prominent enrichment of clusters related to inflammatory processes, such as cytokine production and activity, receptorligand or cell-cell interactions and lymphocyte activation (Supplementary Table 3 ). A number of genes that were differentially expressed in the microarray experiments were selected from the functional groups for verification by quantitative PCR. Indeed, we could corroborate a significant regulation for the cell-cycle regulator CCND2 (cyclin D2), for the transcription factors ETV5 and BCL6, as well as for several cytokines/chemokines, including IL-1α, IL-6, IL-9, IL-12β, CCL3 (MIP-1α) and the receptor IL-2Rα (Figure 2d ), supporting the notion that IL-15 has a significant impact on the mediators of inflammatory responses.
Taken together, our data demonstrate that the IL-15 cytokine/ cytokine receptor system is upregulated in HL and that stimulation of Hodgkin cells with rhIL-15 results in activation of MAP kinase and JAK/STAT5 signal transduction pathways. In addition, functional studies indicate that IL-15 promotes proliferation and apoptosis resistance of Hodgkin tumor cells, thereby extending previous reports that have described mitogenic and anti-apoptotic effects of IL-15 on lymphoid tumor cells of different entities, for example, multiple myeloma, T-cell large granular lymphocyte leukemia and cutaneous T-cell lymphomas. [11] [12] [13] A role of IL-15 signaling in HL tumor biology is further supported by published gene expression data demonstrating that IL-15 and the corresponding receptors are not only upregulated in primary HRS cells compared with various nonmalignant and malignant B-cell populations ( Supplementary Table 5 ), but are also prominent components of deregulated functional pathways in HRS cells. 14, 15 As a major feature of the cellular response to IL-15 stimulation, we identified a significant induction of cytokines and chemokines in Supplementary Table 4 .
HRS cells. Several of these factors, such as IL-6, IL-9 and CCL3, in turn, may have the potential to mediate growth and survival signals for HRS cells as well as to attract or stimulate cells of the tumor microenvironment. 1, 2 In summary, our study identifies IL-15 as a part of the complex interactions between tumor cells and the microenvironment in HL that provides growth and survival signals for HRS cells. Aberrant kinase signaling is a hallmark of myeloid malignancies that has become the focus of targeted therapies due to its integral role in leukemia cell proliferation and survival. 1 In acute myeloid leukemia (AML) in particular, aberrant kinase signaling results from activating mutations of FLT3, KIT and NRAS or mutational inactivation of their negative regulators CBL, PTEN and PTPN11. However, recent genome-wide surveys have revealed that no more than 50% of patients possess activating genetic mutations in these kinase signaling pathways. 2 This suggests that other mechanisms of kinase activation may exist. Ligand-dependent activation of receptor tyrosine kinases (RTKs) has long been recognized as an alternative mechanism of aberrant kinase signaling. Indeed, it is now over three decades since Sporn and Todaro 3 proposed their 'autocrine hypothesis' that postulated the essential functions of secreted factors in the promotion of autonomous cell growth required for malignant transformation. We now recognize many examples of carcinogenic autocrine signaling, involving ligands of the epidermal growth factor (EGF), insulin-like growth factor, platelet-derived growth factor, fibroblast growth factor, EPH, vascular endothelial growth factor, and Fms-like tyrosine kinase 3 (FLT3) and KIT receptors in AML specifically. [4] [5] [6] Recently, autocrine activation of the MET receptor kinase was found in almost 40% of patients with AML, causing enhanced leukemia cell survival owing to aberrant expression of the MET ligand hepatocyte growth factor (HGF) that could be blocked by the competitive RTK inhibitor crizotinib. 7, 8 However, translation of these findings into therapeutic clinical trials remains hindered by limited knowledge about the specific subtypes of AML in which MET activation occurs and by the development of resistance to MET kinase inhibitors due to the overexpression of HGF that adaptively reactivates MET signaling. 8 Here, using reverse-phase protein arrays (RPPA) and mathematical modeling of ligand-dependent MET receptor activation, we determined signaling pathways associated with MET activation in primary AML cells and defined specific strategies to achieve durable inhibition of ligand-dependent kinase signaling in AML. Proteomic RPPA profiling of 511 AML patient specimens collected at the University of Texas M.D. Anderson Cancer Center was done using previously described methods, with experimental details and patient characteristics described in detail elsewhere. 9, 10 Matched peripheral blood and bone marrow samples were available for 140 patients. Paired primary and relapse samples were available for 48 of the AML and 1 of the acute promyelocytic leukemia patients. Outcome analysis was restricted to newly diagnosed patients. The majority of AML patients received arabinofuranosyl cytidine (Ara-C)-based therapy, while acute promyelocytic leukemia patients received combination all-trans retinoic acid therapy. 9 The statistical methods used in this study are described elsewhere in detail, 9 including the use of Super-Curve algorithms, paired t-tests, Bonferroni multiple-hypothesis corrections, mixed-effects linear models and Pearson and Spearman correlation analysis.
Using the RPPA approach, we found that 11% of all AML, 43% of acute promyelocytic leukemia, 9% of newly diagnosed, as well as Accepted article preview online 26 December 2014; advance online publication, 20 January 2015
